haemophilia B


Also found in: Dictionary, Medical, Encyclopedia, Wikipedia.
Related to haemophilia B: haemophilia A, Hæmophilia A, Haemophilia C
Graphic Thesaurus  🔍
Display ON
Animation ON
Legend
Synonym
Antonym
Related
  • noun

Synonyms for haemophilia B

a clotting disorder similar to hemophilia A but caused by a congenital deficiency of factor IX

References in periodicals archive ?
The bleeding episodes are treated with factor replacement therapy with either factor VIII for haemophilia A and factor IX for haemophilia B or with cryoprecipitate or fresh frozen plasma.
In our study, majority (75%) of children were found to have Haemophilia A and only (25%) were having Haemophilia B.
Swedish Orphan Biovitrum AB (Sobi) (STO:SOBI), a specialty healthcare company dedicated to rare diseases, reported on Friday that it has received approval from the Swiss Agency for Therapeutic Products, Swissmedic, for Alprolix (eftrenonacog alfa), which is indicated for both on-demand and prophylaxis treatment of previously treated haemophilia B patients.
According to Sobi, Alprolix is the only recombinant factor IX Fc Fusion protein therapy approved in Switzerland for the treatment of haemophilia B, a rare, genetic disorder in which the ability of a person's blood to clot is impaired.
While this patient was discovered to have haemophilia A, similar reports have been documented in patients with haemophilia B.
In this case, an orbital decompression was performed to relieve the pressure on the optic nerve, and the child was subsequently diagnosed with mild haemophilia B.
Patients and Methods: Total 45 patients of Haemophilia B already enrolled in the Haemophilia society of Pakistan Lahore chapter were included in this study.
Post circumcision bleeding was found to be the most common first episode of bleeding in patients of haemophilia B 29 (64.
4] Kar A et al studied 1467 patients from Maharashtra and found the ratio of haemophilia A to haemophilia B patients was 4.
Under the terms of the agreement with WFH, at least 85 percent of donated factor will be Antihemophilic Factor VIII (Recombinant), Fc Fusion Protein for the treatment of haemophilia A, with the remainder comprised of Coagulation Factor IX (Recombinant), Fc Fusion Protein for the treatment of haemophilia B.
The first is IB1001, an intravenous (IV) recombinant factor IX (FIX) product being developed for the treatment and prevention of bleeding in individuals with haemophilia B.